1. Home
  2. SCD vs FHTX Comparison

SCD vs FHTX Comparison

Compare SCD & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LMP Capital and Income Fund Inc.

SCD

LMP Capital and Income Fund Inc.

HOLD

Current Price

$14.88

Market Cap

255.4M

Sector

Finance

ML Signal

HOLD

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

HOLD

Current Price

$4.43

Market Cap

246.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCD
FHTX
Founded
2003
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
255.4M
246.6M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SCD
FHTX
Price
$14.88
$4.43
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$11.83
AVG Volume (30 Days)
62.6K
207.6K
Earning Date
01-01-0001
11-05-2025
Dividend Yield
9.63%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$24,518,000.00
Revenue This Year
N/A
$42.43
Revenue Next Year
N/A
$14.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.33
$2.95
52 Week High
$15.87
$8.08

Technical Indicators

Market Signals
Indicator
SCD
FHTX
Relative Strength Index (RSI) 55.07 48.26
Support Level $14.65 $4.40
Resistance Level $14.94 $4.87
Average True Range (ATR) 0.23 0.37
MACD 0.08 -0.03
Stochastic Oscillator 93.04 14.33

Price Performance

Historical Comparison
SCD
FHTX

About SCD LMP Capital and Income Fund Inc.

Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships. Maximum investment in Sales in the IT sector, Cheniere Energy in the energy sector, Ares Management and U.S. Bancorp in the financials sector and Lennar in the consumer discretionary sector, and etc.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Share on Social Networks: